Gilead Sciences, Inc. $GILD Stock Bought by Royal Fund Management LLC

Royal Fund Management LLC increased its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 827.4% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 23,861 shares of the biopharmaceutical company’s stock after buying an additional 21,288 shares during the period. Royal Fund Management LLC’s holdings in Gilead Sciences were worth $3,557,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also added to or reduced their stakes in GILD. Bank of Nova Scotia acquired a new position in Gilead Sciences in the second quarter valued at about $100,056,000. Groupe la Francaise grew its stake in Gilead Sciences by 30.9% during the second quarter. Groupe la Francaise now owns 49,627 shares of the biopharmaceutical company’s stock worth $6,270,000 after buying an additional 11,712 shares in the last quarter. OMERS ADMINISTRATION Corp acquired a new stake in Gilead Sciences during the second quarter worth about $55,754,000. Baird Financial Group Inc. grew its stake in Gilead Sciences by 3.6% during the second quarter. Baird Financial Group Inc. now owns 292,295 shares of the biopharmaceutical company’s stock worth $36,929,000 after buying an additional 10,206 shares in the last quarter. Finally, Headlands Technologies LLC bought a new position in Gilead Sciences in the 2nd quarter valued at about $6,251,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Key Stories Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Earnings expectations are supportive. Analysts expect Gilead to potentially beat its upcoming third-quarter estimates, supported by favorable estimate revisions and the company’s history of exceeding consensus forecasts. A strong report or upbeat outlook could reinforce the recent momentum. Gilead Sciences Expected to Beat Earnings Estimates
• Positive Sentiment: Oncology pipeline receives a potential boost. Gilead and BioNTech entered a clinical-trial collaboration and supply agreement to test BioNTech’s pumitamig with Gilead’s TROP2-directed antibody-drug conjugate sacituzumab govitecan in the Phase 3 ROSETTA Breast-01 trial for advanced triple-negative breast cancer. Success could expand the commercial opportunity for Trodelvy and support Gilead’s strategy of building growth beyond HIV. BioNTech and Gilead to Test Drug Combination
• Positive Sentiment: Investors are highlighting longer-term growth drivers. A bullish investment thesis points to Gilead’s durable HIV franchise, oncology expansion and potential for pipeline-led growth without relying primarily on acquisitions. Bank of America also reportedly expects additional upside, adding to the positive analyst narrative. Bank of America Analyst Expects Gilead Stock to Rise
• Neutral Sentiment: Upcoming liver-disease data could provide another catalyst. Gilead plans to present clinical and real-world evidence on primary biliary cholangitis and chronic hepatitis delta at The Liver Meeting in November. The data may support confidence in long-term treatment durability and disease management, although the investment impact will depend on the results. Gilead to Present New Liver-Disease Data
• Negative Sentiment: Valuation and clinical execution remain risks. The shares recently declined during one session despite broader market gains, indicating some sensitivity to profit-taking or company-specific concerns. The BioNTech program is still dependent on Phase 3 results, while the stock’s proximity to its high leaves less room for disappointment if earnings or pipeline data fall short. Gilead Stock Drops Despite Market Gains

Gilead Sciences Stock Up 2.4%

Shares of NASDAQ GILD opened at $157.19 on Friday. The company has a current ratio of 1.27, a quick ratio of 1.09 and a debt-to-equity ratio of 2.03. The company has a market cap of $194.91 billion, a price-to-earnings ratio of -58.87 and a beta of 0.31. Gilead Sciences, Inc. has a 12 month low of $114.02 and a 12 month high of $160.51. The stock has a 50-day moving average price of $148.74 and a two-hundred day moving average price of $137.72.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) EPS for the quarter, topping analysts’ consensus estimates of ($7.25) by $0.50. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. The firm had revenue of $7.80 billion during the quarter, compared to analysts’ expectations of $7.40 billion. During the same quarter in the prior year, the business earned $2.01 earnings per share. The business’s revenue for the quarter was up 10.6% compared to the same quarter last year. As a group, analysts forecast that Gilead Sciences, Inc. will post -0.47 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 29th. Investors of record on Tuesday, September 15th were given a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a yield of 2.1%. The ex-dividend date was Tuesday, September 15th. Gilead Sciences’s dividend payout ratio is currently -122.85%.

Insiders Place Their Bets

In other news, Director Anthony Welters sold 18,000 shares of the company’s stock in a transaction on Wednesday, August 26th. The shares were sold at an average price of $148.62, for a total transaction of $2,675,160.00. Following the completion of the transaction, the director directly owned 12,894 shares in the company, valued at approximately $1,916,306.28. This represents a 58.26% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the company’s stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $156.22, for a total transaction of $468,660.00. Following the transaction, the chief financial officer owned 161,096 shares of the company’s stock, valued at $25,166,417.12. This trade represents a 1.83% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 111,000 shares of company stock worth $15,877,860 over the last 90 days. Insiders own 0.30% of the company’s stock.

Analyst Ratings Changes

Several research firms have commented on GILD. Jefferies Financial Group restated a “buy” rating on shares of Gilead Sciences in a research report on Friday. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $155.00 price target on shares of Gilead Sciences in a report on Thursday, October 8th. Morgan Stanley reduced their price target on shares of Gilead Sciences from $165.00 to $163.00 and set an “overweight” rating on the stock in a research report on Wednesday, October 7th. Royal Bank Of Canada lifted their price objective on shares of Gilead Sciences from $123.00 to $126.00 and gave the company a “sector perform” rating in a research note on Thursday, October 8th. Finally, Barclays decreased their price objective on shares of Gilead Sciences from $155.00 to $145.00 and set an “equal weight” rating on the stock in a research note on Wednesday, July 29th. Twenty-three research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $159.63.

Gilead Sciences Profile

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company is best known for its HIV treatments, including Biktarvy, Descovy, Genvoya and Truvada, as well as therapies for chronic hepatitis B and hepatitis C. Its portfolio also includes Veklury (remdesivir), an antiviral treatment for COVID-19.

Gilead has expanded into oncology and cell therapy through products such as Trodelvy and the CAR T-cell therapies Yescarta and Tecartus, which are developed and marketed through its Kite subsidiary.